Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
19,667,509
-
Number of holders
-
207
-
Total 13F shares, excl. options
-
16,143,355
-
Shares change
-
+357,774
-
Total reported value, excl. options
-
$1,152,971,286
-
Value change
-
+$28,617,779
-
Put/Call ratio
-
72%
-
Number of buys
-
95
-
Number of sells
-
-88
-
Price
-
$71.42
Significant Holders of LIGAND PHARMACEUTICALS INC - Common Stock (LGND) as of Q4 2023
233 filings reported holding LGND - LIGAND PHARMACEUTICALS INC - Common Stock as of Q4 2023.
LIGAND PHARMACEUTICALS INC - Common Stock (LGND) has 207 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16,143,355 shares
of 19,667,509 outstanding shares and own 82% of the company stock.
Largest 10 shareholders include BlackRock Inc. (2,962,314 shares), VANGUARD GROUP INC (1,876,514 shares), JANUS HENDERSON GROUP PLC (1,343,154 shares), MACQUARIE GROUP LTD (987,354 shares), STATE STREET CORP (668,284 shares), DIMENSIONAL FUND ADVISORS LP (661,298 shares), Stephens Investment Management Group LLC (659,434 shares), VILLERE ST DENIS J & CO LLC (428,051 shares), GEODE CAPITAL MANAGEMENT, LLC (370,815 shares), and Pacer Advisors, Inc. (325,727 shares).
This table shows the top 207 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.